Pfizer (NYSE:PFE) Stock Price Down 0.1% – Here’s What Happened

Pfizer Inc. (NYSE:PFE)’s share price was down 0.1% during trading on Friday . The stock traded as low as $22.34 and last traded at $22.51. Approximately 10,162,021 shares changed hands during mid-day trading, a decline of 75% from the average daily volume of 40,377,323 shares. The stock had previously closed at $22.54.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Stock Down 3.0 %

The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $126.67 billion, a P/E ratio of 15.80, a PEG ratio of 0.64 and a beta of 0.58. The company’s 50 day moving average price is $24.02 and its two-hundred day moving average price is $25.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was down 7.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.82 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.72%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Institutional Trading of Pfizer

Institutional investors and hedge funds have recently modified their holdings of the company. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer during the 4th quarter valued at approximately $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC raised its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer during the fourth quarter worth $28,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.